Investigating a new treatment for acute ischemic stroke using a specific inhibitor.
Official title: Soluble Epoxide Hydrolase Inhibitor GSK2256294 for Acute Ischemic Stroke
Funded at Oregon Health & Science University · NIH-11042219 · Data updated 2026-11-12
This study is looking at how a medication called GSK2256294 might help protect the brain during a stroke by boosting helpful substances that reduce damage and improve blood flow, and it's for both younger and older patients, including those with diabetes and high blood pressure.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oregon Health & Science University NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project start | March 15, 2023 |
| Project end | February 28, 2026 |
| Funding year | 2025 |
| Award (this year) | $311,850 |
| NIH project number | 5U01NS132345-03 |
| Project ID | NIH-11042219 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include adults who have experienced an acute ischemic stroke, particularly those with underlying conditions like diabetes or hypertension.
✕Less likely to help
Patients who have not experienced an acute ischemic stroke or those with contraindications to the treatment may not benefit from this research.
What this research studies
This research focuses on the effects of GSK2256294, an FDA-approved soluble epoxide hydrolase inhibitor, on protecting the brain during acute ischemic stroke. The study aims to increase levels of beneficial brain lipid mediators that can help reduce brain damage, inflammation, and improve blood flow. By examining the outcomes in both young and older patients, including those with diabetes and hypertension, the research seeks to establish the efficacy and safety of this treatment in a clinical setting. Previous trials have shown promise, indicating that this approach could lead to better recovery outcomes for stroke patients.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options and recovery outcomes for patients suffering from acute ischemic stroke.
How similar studies have gone: Previous research has shown promising results with similar approaches, indicating potential for significant advancements in stroke treatment.
Where this research is happening
-
Oregon Health & Science University
Portland, United States Active
Researchers
- Principal investigator: Alkayed, Nabil J — Oregon Health & Science University
- Study coordinator: Alkayed, Nabil J
Related research
Other NIH-funded projects on the same topics.
-
Targeted nanomedicine to protect the brain after stroke
A targeted drug-delivery approach aims to boost blood-brain barrier repair and reduce brain damage after an acute ischemic stroke in patients at risk.
-
Modeling Acute Ischemic Stroke to Improve Mechanical Thrombectomy
A research project is creating better computer models and animal studies to help remove clots more safely and effectively in people who have an acute ischemic stroke.
-
Nanoparticle-delivered tPA to overcome clot resistance in acute ischemic stroke
A Mayo Clinic team is testing a nanoparticle-delivered tPA approach to help dissolve clots more effectively in people with acute ischemic stroke due to large vessel blockage.
-
Engineered tissue regulatory T cells as a treatment for stroke
A new off-the-shelf cell therapy using engineered regulatory T cells could help people who have an ischemic stroke recover by reducing inflammation and promoting tissue repair.
-
Fast penumbral imaging to guide stroke treatment
Aims to develop quick MRI techniques to identify tissue at risk in acute ischemic stroke and help decide whether to use advanced clot-busting treatment.
-
Circadian factors shaping reperfusion success in acute stroke
This grant looks at how the body’s internal clock might influence how well stroke patients respond to clot-busting or clot-removal treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.